Evidence Report/Technology Assessment
Number 77

Management of Treatment-Resistant Epilepsy

Volume 2. Evidence Tables

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
www.ahrq.gov

Contract No. 290-97-0020

Prepared by:
ECRI, Plymouth Meeting, PA
Health Technology Assessment Group

Investigators
Richard Chapell, Ph.D.
James Reston, Ph.D.
David Snyder, Ph.D.
Jonathan Treadwell, Ph.D.
Stephen Tregear, Ph.D.
Charles Turkelson, Ph.D

AHRQ Publication No. 03-0028
May 2003

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Suggested Citation:
Chapell R, Reston J, Snyder D. Management of Treatment-Resistant Epilepsy. Evidence Report/Technology Assessment No. 77. (Prepared by the ECRI Evidence-based Practice Center under Contract No 290-97-0020.) AHRQ Publication No. 03-0028. Rockville, MD: Agency for Healthcare Research and Quality. May 2003.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers—patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services.

Contents

Volume 2

Abbreviations used in the Evidence Tables xii

Question 1 1
- Evidence Table 1. Definitions of treatment resistance in clinical studies 1
- Evidence Table 2. Definitions of treatment resistance in clinical guidelines 4
- Evidence Table 3. Definitions of treatment resistance in review articles 5
- Evidence Table 4. Inclusion/exclusion criteria implying a definition of treatment resistance 9
- Evidence Table 5. Implied definitions from inclusion/exclusion criteria 14

Question 2 15
- Evidence Table 6. Evidence base and important study design characteristics for Question 2A 15
- Evidence Table 7. Study characteristics: Inclusion/exclusion criteria 17
- Evidence Table 8. Patient characteristics for Question 2A 18
- Evidence Table 9. Rediagnosis data 19
- Evidence Table 10. Meta-analysis of non-epileptic seizure prevalence data 20
- Evidence Table 11. Number of studies addressing each diagnostic 21
- Evidence Table 12. Articles addressing blood prolactin level measurement excluded for quality reasons 24
- Evidence Table 13. Quality of reporting: articles describing studies of blood prolactin level measurement 25
- Evidence Table 14. Study design characteristics in studies of blood prolactin level measurement 26
- Evidence Table 15. Definitions of diagnostic groups used in studies of blood prolactin level measurement 27
- Evidence Table 16. Protocols for measurement of blood prolactin levels 28
- Evidence Table 17. Inclusion / exclusion criteria in studies of blood prolactin level measurement 29
- Evidence Table 18. Patient characteristics in studies of blood prolactin level measurement 30
- Evidence Table 19. Dichotomous diagnostic performance data: definitions 31
- Evidence Table 20. Dichotomous diagnostic performance data in studies of blood prolactin level measurement 32
- Evidence Table 21. Continuous diagnostic performance data in studies of blood prolactin level measurement 34
- Evidence Table 22. Articles addressing Minnesota Multiphasic Personality Inventory excluded for quality reasons 35
- Evidence Table 23. Articles addressing video EEG excluded for quality reasons 35
- Evidence Table 24. Articles addressing ambulatory EEG excluded for quality reasons 35
- Evidence Table 25. Articles included in previous technology assessments of utility of video-EEG 36

Question 3 38
Evidence Table 26. Studies that provided evidence indicating that not all patients were optimized prior to study entry 38

Question 4 40
Evidence Table 27. General information for studies of sequential monotherapy 40
Evidence Table 28. Design characteristics in studies of sequential monotherapy 42
Evidence Table 29. Reporting characteristics in trials of sequential monotherapy 44
Evidence Table 30. Drug characteristics in studies of sequential monotherapy 45
Evidence Table 31. Numbers of patients and attrition in studies of sequential monotherapy 46
Evidence Table 32. Age, gender, and duration of condition of patients in studies of sequential monotherapy 47
Evidence Table 33. Baseline seizure frequencies and specific types of partial seizures in studies of sequential monotherapy 48
Evidence Table 34. Known etiology and prior drugs in studies of sequential monotherapy. 50
Evidence Table 35. Seizure frequency outcomes in studies of sequential monotherapy 52
Evidence Table 36. Adverse effects in studies of sequential monotherapy 60
Evidence Table 37. Quality of life outcomes and mood outcomes in studies of sequential monotherapy 66
Evidence Table 38. Cognitive function outcomes in studies of sequential monotherapy 70
Evidence Table 39. Scales used to measure quality of life in trials of sequential monotherapy 72
Evidence Table 40. Scales used to measure mood in trials of sequential monotherapy 72
Evidence Table 41. Scales used to measure cognitive function in trials of sequential monotherapy 73
Evidence Table 42. Mortality in trials of sequential monotherapy 74
Evidence Table 43. General information on studies of polytherapy 75
Evidence Table 44. Design characteristics of studies of polytherapy 79
Evidence Table 45. Reporting characteristics of trials of polytherapy 83
Evidence Table 46. Drug characteristics in studies of polytherapy 85
Evidence Table 47. Numbers of patients and attrition in studies of polytherapy 88
Evidence Table 48. Age, gender, and duration of condition of patients in studies of polytherapy 92
Evidence Table 49. Baseline seizure frequencies in studies of polytherapy 96
Evidence Table 50. Specific types of generalized seizures in studies of polytherapy 99
Evidence Table 51. Specific types of partial seizures seizures in studies of polytherapy 103
Evidence Table 52. Known etiology and prior AEDs use in studies of polytherapy 106
Evidence Table 53. Prior drugs in studies of polytherapy 109
Evidence Table 54. Tests of potential selection bias in studies of polytherapy 112
Evidence Table 55. Overall test of age selection bias in trials of polytherapy 115
Evidence Table 56. Overall test of gender selection bias in studies of polytherapy 116
Evidence Table 57. Overall test of duration of condition selection bias in trials of polytherapy 117
Evidence Table 58. Overall test of prior drug selection bias in trials of polytherapy 118
Evidence Table 59. Seizure frequency outcomes in studies of polytherapy 119
Evidence Table 60. Adverse effects in studies of polytherapy 163

Evidence Table 61. Quality of life outcomes and mood outcomes in studies of polytherapy 195
Evidence Table 62. Cognitive function outcomes in studies of polytherapy.....197
Evidence Table 63. Meta-analysis of seizure freedom in trials of polytherapy, high dose groups.....198
Evidence Table 64. Meta-analysis of seizure freedom in trials of polytherapy, low dose groups.....199
Evidence Table 65. Sensitivity analyses of seizure freedom in trials of polytherapy, high dose groups.....200
Evidence Table 66. Sensitivity analyses of seizure freedom in trials of polytherapy, low dose groups.....200
Evidence Table 67. Meta-analysis of 50% reduction in trials of polytherapy, high dose groups.....201
Evidence Table 68. Meta-analysis of 50% reduction in trials of polytherapy, low dose groups.....202
Evidence Table 69. Sensitivity analyses of 50% reduction in trials of polytherapy, high dose groups.....203
Evidence Table 70. Sensitivity analyses of 50% reduction in trials of polytherapy, low dose groups.....203
Evidence Table 71. Meta-analysis of any reduction in trials of polytherapy, high dose groups 203
Evidence Table 72. Meta-analysis of any reduction in trials of polytherapy, low dose groups 204
Evidence Table 73. Sensitivity analyses of any reduction in trials of polytherapy, high dose groups.....204
Evidence Table 74. Sensitivity analyses of any reduction in trials of polytherapy, low dose groups.....204
Evidence Table 75. Meta-analysis of any increase in trials of polytherapy, high dose groups 205
Evidence Table 76. Meta-analysis of any increase in trials of polytherapy, low dose groups 205
Evidence Table 77. Sensitivity analyses of any increase in trials of polytherapy, high dose groups.....205
Evidence Table 78. Sensitivity analyses of any increase in trials of polytherapy, low dose groups.....206
Evidence Table 79. Meta-analysis of trial exits due to adverse effects in trials of polytherapy, high dose groups 206
Evidence Table 80. Meta-analysis of trial exits due to adverse effects in trials of polytherapy, low dose groups.....208
Evidence Table 81. Sensitivity analyses of trial exits due to adverse effects in trials of polytherapy, high dose groups 209
Evidence Table 82. Sensitivity analyses of trial exits due to adverse effects in trials of polytherapy, low dose groups.....209
Evidence Table 83. Scales used to measure quality of life in trials of polytherapy.....210
Evidence Table 84. Scales used to measure mood in trials of polytherapy 210
Evidebce Table 85. Scales used to measure cognitive function in trials of polytherapy 211

Evidence Table 86. Mortality results in trials of polytherapy.....212
Evidence Table 87. Studies of optimized current therapy that met the inclusion criteria 213
Evidence Table 88. Excluded articles examining drug optimization strategies.....213
Evidence Table 89. General information of studies of optimized current therapy.....214
Evidence Table 90. Design characteristics of studies of optimized current therapy.....216
Evidence Table 91. Reporting characteristics of trials of optimized current therapy.....218
Evidence Table 92. Treatment descriptions, numbers of patients and attrition in studies of optimized current therapy.....219
Evidence Table 93. Age, gender, and duration of condition of patients in studies of optimized current therapy.....221
Evidence Table 94. Baseline seizure frequencies and specific types of partial seizures in studies of optimized current therapy.....222
Evidence Table 95. Specific types of generalized seizures in studies of optimized current therapy.....223
Evidence Table 96. Specific types of partial seizures in studies of optimized current therapy 224
Evidence Table 97. Known etiology and prior AED use in studies of optimized current therapy.....225
Evidence Table 98. Prior AEDs used in studies of optimized current therapy.....226
Evidence Table 99. Outcomes in studies of optimized current therapy – changes in seizure frequency.....227
Evidence Table 100. Adverse effects in studies of optimized current therapy.....237
Evidence Table 101. Comparison of patients in drug reduction and control arms of controlled trials.....246

Question 5.....249
Evidence Table 102. All studies meeting the inclusion criteria for surgical interventions and the interventions examined.....249
Evidence Table 103. Studies of temporal lobe surgery – general study information.....255
Evidence Table 104. Studies of frontal lobe surgery – general study information.....264
Evidence Table 105. Studies of multiple subpial transection – general study information.266
Evidence Table 106. Studies of hemispherectomy – general study information.....267
Evidence Table 107. Studies of corpus callosotomy – general study information.....268
Evidence Table 108. Studies with epilepsy surgery control patients – general study information.....271
Evidence Table 109. Studies excluded from the evidence base for seizure-free outcomes after temporal lobe surgery.....271
Evidence Table 110. Patient characteristics for studies of temporal lobe surgery reporting seizure-free outcome measurements 272
Evidence Table 111. Studies of temporal lobe surgery that reported patients as seizure-free with no auras[a] 280
Evidence Table 112. Studies of temporal lobe surgery that reported patients as seizure-free with auras[a] 282
Evidence Table 113. Studies of surgery control patients reporting seizure-free outcome measurements.....284
Evidence Table 114. Studies with epilepsy surgery control patients – reasons for patients not to receive surgery.....285

Evidence Table 115. Comparisons of summary estimates based on study level characteristics for temporal lobe surgery studies reporting seizure-free with no auras [a] 286
Evidence Table 116. Comparisons of summary estimates based on study level characteristics for temporal lobe surgery studies reporting seizure-free with auras. [a] 286
Evidence Table 117. Studies of temporal lobe surgery that reported patients as Engel class I 287
Evidence Table 118. Studies of temporal lobe surgery reporting Engel class I – data used in meta-regression 289
Evidence Table 119. Results of meta-regression of studies of temporal lobe surgery reporting Engel class I 291
Evidence Table 120. Studies of temporal lobe surgery that reported patients as seizure-free undefined 292
Evidence Table 121. Studies of temporal lobe surgery reporting seizure-free undefined – data used in meta-regression. 293
Evidence Table 122. Results of meta-regression of studies of temporal lobe surgery reporting seizure-free undefined 294
Evidence Table 123. Studies of temporal lobe surgery reporting relationships between patient or study characteristics and treatment outcome 295
Evidence Table 124. Studies of temporal lobe surgery reporting relationships between patient characteristics and treatment outcome – other study variables 296
Evidence Table 125. Studies of temporal lobe surgery reporting individual patient age at surgery.....297
Evidence Table 126. Sensitivity analysis of studies of temporal lobe surgery reporting individual patient age at surgery for successful and nonsuccessful patients.....298
Evidence Table 127. Studies of temporal lobe surgery reporting individual age at seizure onset 299
Evidence Table 128. Sensitivity analysis of studies of temporal lobe surgery reporting individual patient age at seizure onset.....300
Evidence Table 129. Studies of temporal lobe surgery reporting individual patients duration of epilepsy prior to surgery 301
Evidence Table 130. Sensitivity analysis of studies of temporal lobe surgery reporting individual patient duration of epilepsy prior to surgery.....301
Evidence Table 131. Studies of temporal lobe surgery reporting number of male and female patients with successful and nonsuccessful surgery.....302
Evidence Table 132. Studies of temporal lobe surgery reporting number of male and female patients with successful and nonsuccessful surgery – data used in meta-regression....303
Evidence Table 133. Results of meta-regression of studies of temporal lobe surgery reporting percentage of male and female patients among patients with successful and nonsuccessful surgery 304
Evidence Table 134. Studies of temporal lobe surgery reporting the number of left-sided and right-sided operations with successful and nonsuccessful surgery outcome measurements.....307
Evidence Table 135. Sensitivity analysis of studies of temporal lobe surgery reporting the number of left side and right side surgeries among patients with successful and nonsuccessful surgery 308

Evidence Table 136. Studies of temporal lobe surgery reporting number of simple partial seizure (SPS) patients with successful and nonsuccessful surgery. 309
Evidence Table 137. Sensitivity analysis of studies of temporal lobe surgery reporting the percentage of patients with simple partial seizures among patients with successful and nonsuccessful surgery 309
Evidence Table 138. Studies of temporal lobe surgery reporting number of secondarily generalized seizure (SGS) patients with successful and nonsuccessful surgery.....310
Evidence Table 139. Studies of temporal lobe surgery reporting number of secondarily generalized seizure (SGS) patients with successful and nonsuccessful surgery – data used in meta-regression.....310
Evidence Table 140. Results of meta-regression of studies of temporal lobe surgery reporting the number of patients with secondarily generalized seizures among patients with successful and nonsuccessful surgery.....311
Evidence Table 141. Studies of temporal lobe surgery reporting quality of life outcome measurements 316
Evidence Table 142. Studies of temporal lobe surgery reporting employment data.....317
Evidence Table 143. Studies of temporal lobe surgery reporting the ability to attend or remain in school after surgery.....317
Evidence Table 144. Studies of temporal lobe surgery reporting ability to obtain a driver's license after surgery.....317
Evidence Table 145. Studies reporting new cases of depression after temporal lobe surgery 318
Evidence Table 146. Patient characteristics for studies of temporal lobe surgery reporting new cases of depression 319
Evidence Table 147. Results of meta-analysis of studies of temporal lobe surgery reporting new cases of depression after surgery.....321
Evidence Table 148. Studies of temporal lobe surgery reporting new cases of depression after surgery – data used in meta-regression.....322
Evidence Table 149. Results of meta-regression of studies of temporal lobe surgery reporting new cases of depression after surgery 323
Evidence Table 150. Studies reporting new cases of psychosis after temporal lobe surgery 325
Evidence Table 151. Patient characteristics for studies of temporal lobe surgery reporting new cases of psychosis 326
Evidence Table 152. Studies of temporal lobe surgery reporting new cases of psychosis after surgery.....327
Evidence Table 153. Studies of temporal lobe surgery reporting both the number of patients with IQ changes after surgery and the pre-treatment and post-treatment mean IQ 328
Evidence Table 154. Patient characteristics for studies of temporal lobe surgery reporting individual patient changes in IQ.....329
Evidence Table 155. Studies of temporal lobe surgery reporting individual patient changes in verbal IQ after surgery.....330
Evidence Table 156. Studies of temporal lobe surgery reporting individual patient changes in verbal IQ – changes in mean IQ 330
Evidence Table 157. Sensitivity analysis of studies of temporal lobe surgery reporting mean IQ.....331

Evidence Table 158. Studies of temporal lobe surgery reporting individual changes in patient memory after surgery 332
Evidence Table 159. Studies of temporal lobe surgery reporting individual patient changes in memory function 332
Evidence Table 160. Patient characteristics for studies of temporal lobe surgery reporting complications due to surgery 333
Evidence Table 161. Complications due to surgery reported in studies of temporal lobe surgery 338
Evidence Table 162. Patient characteristics for studies of temporal lobe surgery reporting surgery related mortality 342
Evidence Table 163. Corpus callosotomy studies excluded from the evidence base for seizure frequency outcomes 347
Evidence Table 164. Patient characteristics in studies of corpus callosotomy reporting seizure frequency outcomes 347
Evidence Table 165. Studies of corpus callosotomy reporting a percentage reduction in seizure frequency 349
Evidence Table 166. Studies of corpus callosotomy reporting a 90% or greater reduction in frequency of all seizure types 350
Evidence Table 167. Studies of corpus callosotomy reporting patients who received no benefit from surgery 351
Evidence Table 168. Studies of corpus callosotomy reporting patients as completely seizure-free 351
Evidence Table 169. Studies of corpus callosotomy reporting pre- and postsurgery seizure frequency [a] 352
Evidence Table 170. Studies of corpus callosotomy reporting relationships between patient or study characteristics and treatment outcome 352
Evidence Table 171. Studies of corpus callosotomy reporting individual patient age at surgery 353
Evidence Table 172. Sensitivity analysis of studies of corpus callosotomy reporting individual patient age at surgery 353
Evidence Table 173. Studies of corpus callosotomy reporting individual patient age at seizure onset 354
Evidence Table 174. Sensitivity analysis of studies of corpus callosotomy reporting individual patient age at seizure onset 354
Evidence Table 175. Studies of corpus callosotomy reporting individual patient duration of epilepsy prior to surgery 355
Evidence Table 176. Sensitivity analysis of studies of corpus callosotomy reporting individual patient duration of epilepsy prior to surgery 355
Evidence Table 177. Studies of corpus callosotomy reporting patients who were free of their most disabling seizures 356
Evidence Table 178. Studies of corpus callosotomy reporting patients who were free of generalized tonic-clonic seizures. 357
Evidence Table 179. Studies of corpus callosotomy reporting patients who were free of generalized tonic-clonic seizures – data used in meta-regression 357
Evidence Table 180. Results of the meta-regression for studies of corpus callosotomy reporting patients who were free of generalized tonic-clonic seizures after surgery....358

Evidence Table 181. Studies of corpus callosotomy reporting patients who became free of atonic seizures after surgery....360
Evidence Table 182. Studies of corpus callosotomy reporting employment data 360
Evidence Table 183. Studies of corpus callosotomy reporting changes in IQ 360
Evidence Table 184. Patient characteristics from studies of corpus callosotomy reporting complications due to surgery....361
Evidence Table 185. Studies of corpus callosotomy reporting complications – list of complications 363
Evidence Table 186. Patient characteristics from studies of frontal lobe surgery reporting seizure outcome measurements 366
Evidence Table 187. Studies of frontal lobe surgery reporting seizure-free undefined 368
Evidence Table 188. Studies of frontal lobe surgery reporting patients who were seizure-free undefined – data used in meta-regression 368
Evidence Table 189. Results of the meta-regression for studies of frontal lobe surgery reporting patients who were seizure-free undefined 369
Evidence Table 190. Studies of frontal lobe surgery reporting patients with seizure-free outcomes 370
Evidence Table 191. Studies of frontal lobe surgery reporting relationships between patient or study characteristics and treatment outcome 370
Evidence Table 192. Patient characteristics from studies of frontal lobe surgery reporting complications due to surgery....371
Evidence Table 193. Studies of frontal lobe surgery reporting complications – list of complications 372
Evidence Table 194. Patient characteristics from studies of frontal lobe surgery reporting surgery related mortality 373
Evidence Table 195. Patient characteristics from studies of hemispherectomy reporting seizure-free outcome measurements 374
Evidence Table 196. Studies of hemispherectomy reporting seizure outcome measurements 374
Evidence Table 197. Studies of hemispherectomy reporting education data....375
Evidence Table 198. Studies of hemispherectomy reporting changes in IQ....375
Evidence Table 199. Patient characteristics from studies of hemispherectomy reporting complications 375
Evidence Table 200. Studies of hemispherectomy reporting complications – list of complications 377
Evidence Table 201. Patient characteristics in studies of multiple subpial transection....378
Evidence Table 202. Studies of multiple subpial transection reporting seizure frequency outcomes....379
Evidence Table 203. Studies of multiple subpial transection reporting individual patient age at surgery....380
Evidence Table 204. Sensitivity analysis of studies of multiple subpial transection reporting individual patient age at surgery 380
Evidence Table 205. Studies of multiple subpial transection reporting successful surgery among male and female patients 381
Evidence Table 206. Sensitivity analysis of studies of multiple subpial transection reporting successful surgery among male and female patients....381

Evidence Table 207. Studies of multiple subpial transection reporting no benefit [a].....382
Evidence Table 208. Studies of multiple subpial transection reporting complications 383
Evidence Table 209. Studies addressing nondrug, nonsurgery interventions.....384
Evidence Table 210. Articles addressing vagal nerve stimulation (VNS) excluded for quality reasons 386
Evidence Table 211. Quality of reporting in studies of vagal nerve stimulation.....386
Evidence Table 212. Primary characteristics of included studies on vagal nerve stimulation 387
Evidence Table 213. Study characteristics: data collection and analysis for studies of vagal nerve stimulation.....389
Evidence Table 214. Study characteristics: attrition rates in studies of vagal nerve stimulation.....393
Evidence Table 215. Study characteristics: confirmation of diagnosis and definition used in studies of vagal nerve stimulation.....395
Evidence Table 216. Study characteristics: patient selection criteria in studies of vagal nerve stimulation.....397
Evidence Table 217. Study characteristics: settings in studies of vagal nerve stimulation.401
Evidence Table 218. Patient characteristics: baseline demographics in studies of vagal nerve stimulation.....403
Evidence Table 219. Patient characteristics: seizure types and etiology in studies of vagal nerve stimulation.....406
Evidence Table 220. Subpopulations of patients with treatment-resistant epilepsy in whom vagal nerve stimulation was assessed.....410
Evidence Table 221. Individual patient data extracted from Boon (1999) 411
Evidence Table 222. Individual patient data extracted from Chayasirisobhon (2001) 413
Evidence Table 223. Individual patient data extracted from Hosain (2000).....415
Evidence Table 224. Individual patient data extracted from Parker (1999).....416
Evidence Table 225. Individual patient data extracted from Lundgren (1998) 418
Evidence Table 226. Percentage reduction in seizure frequency from baseline in studies of vagal nerve stimulation 420
Evidence Table 227. Percentage change from baseline data in studies of vagal nerve stimulation (results of fixed effects meta-analysis of single treatment arm data).....424
Evidence Table 228. Univariate meta-regression analyses of percentage change from baseline data in studies of vagal nerve stimulation.....425
Evidence Table 229. Difference in absolute seizure frequency in studies of vagal nerve stimulation.....426
Evidence Table 230. Proportion of patients seizure-free in studies of vagal nerve stimulation. 428
Evidence Table 231. Proportion of patients with >50% reduction in seizure frequency in studies of vagal nerve stimulation.....429
Evidence Table 232. Quality of life in studies of vagal nerve stimulation 433
Evidence Table 233. Adverse events in studies of vagal nerve stimulation 435
Evidence Table 234. Mortality in studies of vagal nerve stimulation.....439
Evidence Table 235. Articles addressing the ketogenic diet excluded for quality reasons ..440

Question 6 441

Evidence Table 236. Excluded studies of nondrug, nonsurgical treatments for treatment-resistant epilepsy 441

Question 7 443
Evidence Table 237. Excluded studies of employment and schooling 443

Question 8 444
Evidence Table 238. Excluded studies of mortality rate in patients with treatment-resistant epilepsy 444
Evidence Table 239. Design and conduct of included studies mortality rate in patients with treatment-resistant epilepsy 445
Evidence Table 240. Overall mortality rates in studies of treatment-resistant epilepsy patients 446
Evidence Table 241. Sudden unexpected death rates in studies of treatment-resistant epilepsy patients 447
Evidence Table 242. Drowning rates among patients with treatment-resistant epilepsy 448
Evidence Table 243. Accident-related mortality rates among patients with treatment-resistant epilepsy 449
Evidence Table 244. Automobile accident-related mortality rates among patients with treatment-resistant epilepsy 450
Evidence Table 245. Aspiration-related mortality rates among patients with treatment-resistant epilepsy 450
Evidence Table 246. Pneumonia-related mortality rates among patients with treatment-resistant epilepsy 451
Evidence Table 247. Cardiovascular mortality rates among patients with treatment-resistant epilepsy 451
Evidence Table 248. Cerebrovascular mortality rates among patients with treatment-resistant epilepsy 452
Evidence Table 249. Cancer-related mortality rates among patients with treatment-resistant epilepsy 452
Evidence Table 250. Suicide rates among patients with treatment-resistant epilepsy 453

Question 9 454
Evidence Table 251. Design and conduct of included studies of sudden unexpected death from epilepsy (SUDEP) 454
Evidence Table 252. Correlation between SUDEP and seizure frequency 456
Evidence Table 253. Correlation between SUDEP and seizure frequency 457
Evidence Table 254. Correlation between SUDEP and seizure type 459
Evidence Table 255. Correlation between SUDEP and seizure type 460

Bibliography 461